Damien Marsic, Ph.D., of Porton Advanced Solutions, discusses how the company is leveraging their expertise in capsid engineering to develop more effective adeno-associated viral (AAV) vectors that greatly expand patients’ access to treatments by broadening the range of diseases treatable with next-generation gene therapies.
.svg)
